Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propranolol + sertraline is a combination of two small molecule drugs, each with distinct mechanisms of action and therapeutic uses. Propranolol is a non-selective beta-adrenergic receptor antagonist (beta blocker) primarily used to treat hypertension, angina, arrhythmias, migraine prophylaxis, and the physical symptoms of anxiety. Sertraline is a selective serotonin reuptake inhibitor (SSRI) antidepressant indicated for major depressive disorder, social anxiety disorder, panic disorder, and other psychiatric conditions. When used together—though not available as a fixed-dose combination product—they may be co-prescribed to address both the psychological (sertraline) and physical (propranolol) symptoms of anxiety or related disorders. Caution is advised due to potential pharmacokinetic interactions; sertraline can increase serum concentrations of propranolol by inhibiting its metabolism[1][2][5]. This may enhance propranolol’s effects or side effects such as bradycardia or hypotension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propranolol + sertraline.